FDA Grants Accelerated Approval to Brukinsa for Mantle Cell Lymphoma
Continued approval may be contingent upon verification of clinical benefit in a confirmatory trial.
Lymphoma News
LYMPHOMA ADVISOR
Lymphoma News
Nurse Practitioner-Led Rapid Diagnosis Clinic May Reduce Time to Diagnosis in Lymphoma
Patients referred to the clinic were diagnosed nearly 2 weeks faster compared with historical controls.
Survival Outcomes Associated With Infusion Reactions With Rituximab in Diffuse Large B-Cell Lymphoma
A retrospective cohort analysis found that patients with DLBCL who experienced infusion reactions during treatment with rituximab had prolonged overall survival. In addition, progression-free survival was affected in subsets of patients with DLBCL.
Off-the-Shelf CAR T Cells From Umbilical Cord Blood Show Unique Features
Anti-CD19 chimeric antigen receptor T cells made from umbilical cord blood cells had a distinct phenotype and may offer off-the-shelf potential.
Predictors of Immune Response to Hep B Shot ID’d in Lymphoma
Dose and frequency of vaccination, sex, Ann Arbor stage, ibrutinib impact immunity effects of vaccine
Inferior Response Following Early Relapse in Frontline Treatment for Aggressive B-Cell Lymphomas
Of patients who experienced relapse within 6 months of frontline treatment, 17% achieved a complete response.
Pembrolizumab Shows Benefit in Primary Mediastinal Large B-cell Lymphoma
Pembrolizumab showed clinical benefit in patients with relapsed or refractory primary mediastinal large B-cell lymphoma, according to KEYNOTE-013 and KEYNOTE-170.
Weighing Benefits, Risks of Antenatal Chemotherapy in Pregnant Women With Hodgkin Lymphoma
A retrospective cohort study explored outcomes for pregnant women with HL who received antenatal chemotherapy compared with a match cohort of nonpregnant women.
Long-Term Health Following the Lymphome Malin de Burkitt Chemotherapy Regimen
Survivors treated with 2 different kinds of chemotherapy experienced similar general and mental health, activity limitations, and increase in risk for mortality,
Certain Cytokines Distinguished Malignant Breast Implant-Related Lymphomas
Assay could help clarify pathogenesis of breast-implant related lymphomas.
Differences in Postrelapse Mortality May be Driving Racial/Ethnic Disparities Observed in Children With Hodgkin Lymphoma
Study sought to determine if response to upfront treatment in children and adolescents with Hodgkin lymphoma is influenced by race/ethnicity.
Physician Experience With Rituximab Affected Rate of Early Discontinuation in NHL
Early discontinuation of rituximab in patients with B-cell non-Hodgkin lymphoma was linked with worse survival.
A Salvage Therapy Option for Follicular Lymphoma Makes Headway
A response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone appeared effective as a salvage therapy for follicular lymphoma.
Factors Associated With Low Bone Mineral Density in Blood Cancer Survivors
Older age at diagnosis, white race, and body mass index below the fifth percentile were associated with low bone mineral density.
Switching to Subcutaneous Rituximab Deemed Safe for Non-Hodgkin Lymphoma
For patients with non-Hodgkin lymphoma, switching from intravenous to subcutaneous rituximab appeared to be effective and presented no new safety issues.
Incidence of Late Events After CAR-T Therapy for Relapsed/Refractory B-Cell Malignancies
Infections occurred in 33 of 54 patients for whom data were available, and 80% of infections were treated in an outpatient setting.
Tailored Monitoring May Be Warranted in Patients With Diffuse Large B-Cell Lymphoma
The development of secondary primary malignancies in patients with diffuse large B-cell lymphoma varies in accordance with several risk factors.
Evidence Supporting Use of PET/CT Status as a Predictor of Disease Progression in Follicular Lymphoma
In this study, patients were classified as either PET-negative or PET-positive using the 5-point Deauville criteria.
Low Immune Infiltration Linked to Worse Outcomes in Follicular Lymphoma
Patients with follicular lymphoma who had disease progression within 24 months of diagnosis were found to have lower intratumoral immune infiltration.
Use of Single Tool Insufficient for Measuring Health-Related Quality of Life in Patients With Cutaneous T-Cell Lymphoma
Researchers determined that several validated assessment tools are needed to measure health-related quality of life in patients with cutaneous T-cell lymphoma.
Want to read more?
Please login or register first to view this content.
Next post in Lymphoma
